Document is current
Any future updates will be listed below
-
Authors
Thomas, Mark https://orcid.org/0000-0001-8922-7583
Gois, Pedro Henrique Franca
Butcher, Belinda E.
Ta, Michelle H. T. https://orcid.org/0000-0001-8437-4373
Van Wyk, Greg W.
- License Information
-
More Information
Article History
Received: 10 August 2021
Accepted: 8 November 2021
First Online: 2 December 2021
Declarations
:
: This study was conducted in accordance with all relevant guidelines and regulations. The secondary data analysis of the IMADJIN® dataset, including an informed consent waiver approval, was approved by the Royal Perth Hospital Human Research Ethics Committee (Approval Number: RGS0000003858), Perth, Western Australia.
: Not applicable.
: MT has received lecture fees and advisory board fees, plus international research funding for the TEMPO and OLE studies. PFG has no competing interests to declare. BEB declares medical writing fees and statistical consulting fees paid to WriteSource Medical Pty Ltd. for services provided to the following pharmaceutical companies: AbbVie, Actelion, Alexion, Bayer, BMS, Ferring, George Clinical, Hartmann, Janssen-Cilag Australia, Lilly, Lundbeck, Medlab, Merck, Novartis, Nucleus Network, Pfizer, Pharmaxis, Roche, Sandoz, Sanofi, UCB. MHTT is an employee of Otsuka Australia Pharmaceutical Pty Ltd. GWVW declares strategic and medical consulting fees paid to AIH Consulting Pty Ltd., by Otsuka Australia Pharmaceutical Pty Ltd.
